[Prophylaxis against adverse effects of chemotherapy for HIV positive patients].
Since the era of HAART cancers in patients infected with HIV are responsible for more than 10% of the residual deaths. One of the more important goal to achieve a better prognosis in these patients, is to prevent the adverse drug events. Unfortunately, these adverse events are frequent because of the chemotherapy-antiretrovirals drug-drug interactions, poor physiologic status, hematologic toxicity enhanced by HIV dysmyelopoiesis and infectious complications. The risk is to be unable to pursue the entire therapeutic program. This paper describes how a narrow collaboration between the oncologist and the specialist of HIV disease could prevent such events.
Bentata
Michelle
M
Unité sida, Service de médecine interne, hôpital Avicenne, 125, route de Stalingrad, 93009 Bobigny Cedex. hiv.bentata@avc.ap-hop-paris.fr
D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D004347:Drug Interactions; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D007400:Interprofessional Relations; D008495:Medical Oncology; D009369:Neoplasms / Q000188:drug therapy / Q000821:virology
D000970:Antineoplastic Agents